Humana (NYSE:HUM) Releases FY 2026 Earnings Guidance

Key Points

• FY2026 guidance: Humana set EPS guidance at 9.00 (above the consensus 8.78) while guiding revenue around $160.0 billion, below the consensus $162.6 billion.
• Dividend announced: The company declared a quarterly dividend of $0.885 (annualized $3.54, ~1.5% yield), with the ex‑dividend/record date on June 26 and payment on July 31.
• Market/analyst backdrop: Analysts’ consensus is a “Hold” with a $222.09 target amid recent downgrades, and shares face near‑term catalysts (Q1 earnings) and downside risk tied to Medicare Advantage reimbursement uncertainty.

Humana (NYSE:HUM - Get Free Report) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 9.000- for the period, compared to the consensus EPS estimate of 8.780. The company issued revenue guidance of $160.0B-, compared to the consensus revenue estimate of $162.6 billion.

Humana Price Performance

Shares of HUM opened at $230.32 on Wednesday. The business has a 50-day moving average of $186.35 and a 200-day moving average of $227.34. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.00. The company has a market capitalization of $27.65 billion, a price-to-earnings ratio of 23.45, a price-to-earnings-growth ratio of 2.40 and a beta of 0.44. Humana has a 1 year low of $163.11 and a 1 year high of $315.35.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, beating the consensus estimate of ($4.01) by $0.05. The business had revenue of $32.64 billion for the quarter, compared to analysts' expectations of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.The firm's revenue was up 11.3% on a year-over-year basis. During the same period in the prior year, the business posted ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, equities research analysts anticipate that Humana will post 9.05 earnings per share for the current year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.5%. The ex-dividend date of this dividend is Friday, June 26th. Humana's dividend payout ratio is currently 36.05%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on HUM shares. Weiss Ratings reissued a "sell (d+)" rating on shares of Humana in a research note on Tuesday, April 21st. The Goldman Sachs Group cut their price target on shares of Humana from $215.00 to $158.00 and set a "sell" rating on the stock in a research report on Friday, February 13th. Barclays decreased their price target on Humana from $245.00 to $176.00 and set an "equal weight" rating for the company in a report on Tuesday, February 24th. Evercore lifted their price objective on Humana from $180.00 to $195.00 in a research report on Wednesday, April 8th. Finally, Leerink Partners dropped their price objective on Humana from $267.00 to $185.00 and set a "market perform" rating on the stock in a research note on Thursday, February 12th. Seven equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $222.09.

Insider Activity at Humana

In other news, insider Sanjay K. Shetty bought 810 shares of Humana stock in a transaction dated Monday, February 23rd. The stock was bought at an average cost of $185.21 per share, for a total transaction of $150,020.10. Following the purchase, the insider directly owned 11,657 shares in the company, valued at approximately $2,158,992.97. This represents a 7.47% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is currently owned by corporate insiders.

Humana News Roundup

Here are the key news stories impacting Humana this week:

• Positive Sentiment: New strategic pharmacy tie-up with Mark Cuban’s Cost Plus Drugs expands CenterWell’s distribution and employer-focused drug offerings — a potential margin and growth tailwind if it scales. Humana partners with Mark Cuban's Cost Plus Drugs on technology, distribution
• Positive Sentiment: Medicare Advantage payment rules for 2027 look modestly favorable (CMS projected ~2.48% increase), improving revenue visibility for MA-focused insurers like Humana and supporting sentiment into earnings. Humana rises 3.9% ahead of earnings as Medicare Advantage rate outlook supports sentiment
• Neutral Sentiment: Q1 2026 earnings release is scheduled for April 29 — a near-term catalyst that’s driving positioning; investors will focus on medical-cost trends, membership metrics and FY guidance. Earnings to watch: Humana (HUM) reports Q1 results tomorrow
• Neutral Sentiment: Humana is rallying alongside UnitedHealth as the managed‑care sector rebounds in April; part of the move reflects broader sector rotation rather than company‑specific news. UnitedHealth and Humana Soar in April: Which Healthcare Stock Is Winning and Why
• Negative Sentiment: Analyst and media caution: Humana’s share performance has been volatile this year due to uncertainty around how much the government will pay Medicare Advantage plans — downside risk remains if reimbursement pressure reappears or guidance disappoints. Humana Earnings Could Signal If More Medicare Advantage Members Is a Good Thing

Institutional Investors Weigh In On Humana

A number of hedge funds have recently added to or reduced their stakes in the company. Larson Financial Group LLC raised its position in shares of Humana by 114.1% during the third quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider's stock worth $40,000 after purchasing an additional 81 shares during the period. Fulcrum Asset Management LLP acquired a new stake in Humana in the 3rd quarter valued at $42,000. DV Equities LLC acquired a new stake in Humana in the 4th quarter valued at $43,000. BOKF NA increased its stake in Humana by 4,125.0% during the 3rd quarter. BOKF NA now owns 169 shares of the insurance provider's stock valued at $44,000 after purchasing an additional 165 shares in the last quarter. Finally, Caden Capital Partners LP bought a new stake in Humana during the 4th quarter valued at $112,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Company Profile

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.